A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results